Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016 Summary Global Markets Direct's, '78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Review, H1 2016', provides in depth analysis on 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted pipeline therapeutics. The report provides comprehensive information on the 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - The report reviews 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics and enlists all their major and minor projects - The report assesses 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) Overview 6 Therapeutics Development 7 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Products under Development by Stage of Development 7 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Products under Development by Therapy Area 8 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Products under Development by Indication 9 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Products under Development by Companies 13 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Companies Involved in Therapeutics Development 22 Arno Therapeutics, Inc. 22 Intezyne, Inc 23 Nuevolution AB 24 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Drug Profiles 25 AR-12 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 IT-139 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 NEO-100 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Rasolvir - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecule to Inhibit GRP78 for Oncology - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Dormant Projects 35 78 kda Glucose-Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+)-Binding Protein Grp78 or GRP78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain-Binding Protein or BiP or HSPA5) - Featured News & Press Releases 36 May 13, 2016: NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100 in Recurrent Glioblastoma Multiforme (GBM) 36 Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis 36 Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains 38 Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference 39 Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 40 Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition 41 Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 42 May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 43 May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 44 Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 45 May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012 45 Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer 46 Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339 46 Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339 47 Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Arno Therapeutics, Inc., H1 2016 22 Pipeline by Intezyne, Inc, H1 2016 23 Pipeline by Nuevolution AB, H1 2016 24 Dormant Projects, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
